Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

Diabetes, Obesity & Metabolism
R ChiltonO E Johansen

Abstract

To determine the effects of empagliflozin on blood pressure (BP) and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes mellitus (T2DM). We conducted a post hoc analysis of data from a phase III trial in patients with T2DM and hypertension receiving 12 weeks' empagliflozin and four phase III trials in patients with T2DM receiving 24 weeks' empagliflozin (cohort 1, n = 823; cohort 2, n = 2477). BP was measured using 24-h BP monitoring (cohort 1) or seated office measurements (cohort 2). Empagliflozin reduced systolic BP (SBP) and diastolic BP in both cohorts (p < 0.001 vs placebo), without increasing heart rate. Empagliflozin reduced pulse pressure (PP; adjusted mean difference vs placebo cohort 1: -2.3 mmHg; cohort 2: -2.3 mmHg), mean arterial pressure (MAP; cohort 1, -2.3 mmHg; cohort 2, -2.1 mmHg) and double product (cohort 1, -385 mmHg × bpm; cohort 2, -369 mmHg × bpm) all p < 0.001 vs placebo. There was a trend towards a reduction in the ambulatory arterial stiffness index (AASI) with empagliflozin in cohort 1 (p = 0.059 vs placebo). AASI was not measured in cohort 2. Subgroup analyses showed that there were greater reductions in PP with increasing baseline SBP in cohort 1 (p = 0.092). In...Continue Reading

References

Dec 7, 2002·Hypertension·Brian A MullanDavid R McCance
Mar 15, 2006·Blood Pressure Monitoring·Eamon DolanAlice Stanton
Oct 13, 2009·Diabetes & Metabolism·P M NilssonUNKNOWN Swedish National Diabetes Register (NDR)
Mar 4, 2010·European Heart Journal·Charalambos VlachopoulosChristodoulos Stefanadis
Mar 27, 2010·Journal of the American College of Cardiology·Charalambos VlachopoulosChristodoulos Stefanadis
Apr 7, 2011·The Journal of Clinical Hypertension·Willa A Hsueh, Kathleen Wyne
Feb 1, 2012·Journal of Cardiovascular Translational Research·Jessica E Wagenseil, Robert P Mecham
May 29, 2012·Atherosclerosis·Anastasios KolliasEoin O'Brien
Jun 8, 2013·Vascular Health and Risk Management·James D CameronJirar Topouchian
Mar 4, 2014·Endocrinology and Metabolism Clinics of North America·Guido LastraJames R Sowers
Mar 8, 2014·Journal of the American Society of Hypertension : JASH·William L BakerWilliam B White
Apr 12, 2014·Diabetes Care·Hans-Ulrich HäringUNKNOWN EMPA-REG MET Trial Investigators
May 8, 2014·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Lars RydénJose Luis Zamorano
Oct 2, 2014·Diabetes Care·Ilkka TikkanenUNKNOWN EMPA-REG BP Investigators
Jan 16, 2015·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Silvio E InzucchiOdd Erik Johansen

❮ Previous
Next ❯

Citations

Dec 24, 2015·Expert Opinion on Drug Safety·Ian J NeelandDarren K McGuire
Jan 29, 2016·European Heart Journal·David FitchettUNKNOWN EMPA-REG OUTCOME® trial investigators
Mar 22, 2016·Postgraduate Medicine·Helmut O Steinberg
Aug 18, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Anne E de Leeuw, Rudolf A de Boer
Jun 14, 2016·Expert Opinion on Pharmacotherapy·T D FilippatosM S Elisaf
Jun 9, 2016·Expert Opinion on Drug Safety·Lisa M YounkStephen N Davis
Sep 11, 2016·Trends in Cardiovascular Medicine·David PhamIan J Neeland
Aug 18, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Tushar MadaanAbul Kalam Najmi
Oct 27, 2016·Revista Española De Cardiología·Belén Dalama, Jordi Mesa
Nov 12, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·John E AndersonCharles F Shaefer
Feb 17, 2017·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tomoko YoshikawaYoshitaka Hirooka
Mar 10, 2016·Journal of Diabetes Science and Technology·Daniel Gordin, Per-Henrik Groop
May 21, 2017·The American Journal of Medicine·Son V Pham, Robert Chilton
Jan 20, 2017·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Asadur RahmanAkira Nishiyama
Mar 17, 2017·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Atsushi Tanaka, Koichi Node
Nov 1, 2017·Antioxidants & Redox Signaling·Ioannis Akoumianakis, Charalambos Antoniades
Mar 9, 2018·Heart Failure Reviews·Anne Pernille OfstadOdd Erik Johansen
Jan 13, 2018·Heart Failure Reviews·Abdullah KaplanFouad A Zouein
Aug 25, 2017·European Journal of Heart Failure·Javed ButlerUNKNOWN EMPEROR Trials Program
Jun 20, 2017·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Jaromira GajdovaJosef Zadrazil
Jun 19, 2018·The Annals of Pharmacotherapy·Joseph E CruzMary Barna Bridgeman
Oct 9, 2018·International Journal of Clinical Practice·Marko SkelinDario Rahelić
Jul 19, 2018·American Journal of Physiology. Renal Physiology·K Melissa HallowDavid W Boulton
Nov 23, 2018·Expert Opinion on Drug Metabolism & Toxicology·Alvaro Garcia-RoperoCarlos G Santos-Gallego

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01131676

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.